; of which $353,811,000, to remain available for obligation until September 30, 2026, shall be for procurement; and of which $1,956,973,000, to remain available for obligation until September 30, 2025, shall be for research, development, test and evaluation: Provided, That of the funds provided under this heading for research, development, test and evaluation, not less than $864,500,000 shall be made available to the Defense Health Agency to carry out the congressionally directed medical research programs. Chemical agents and munitions destruction, defense For expenses, not otherwise provided for, necessary for the destruction of the United States stockpile of lethal chemical agents and munitions in accordance with the provisions of section 1412 of the Department of Defense Authorization Act, 1986 ( 50 U.S.C. 1521 ), and for the destruction of other chemical warfare materials that are not in the chemical weapon stockpile, $1,091,844,000, of which $89,284,000 shall be for operation and maintenance, of which not less than $57,875,000 shall be for the Chemical Stockpile Emergency Preparedness Program, consisting of $23,676,000 for activities on military installations and $34,199,000, to remain available until September 30, 2025, to assist State and local governments; and $1,002,560,000, to remain available until September 30, 2025, shall be for research, development, test and evaluation, of which $1,000,467,000 shall only be for the Assembled Chemical Weapons Alternatives program. Drug interdiction and counter-Drug activities, defense (INCLUDING TRANSFER OF FUNDS) For drug interdiction and counter-drug activities of the Department of Defense, for transfer to appropriations available to the Department of Defense for military personnel of the reserve components serving under the provisions of title 10 and title 32, United States Code; for operation and maintenance; for procurement; and for research, development, test and evaluation, $994,490,000, of which $622,593,000 shall be for counter-narcotics support